NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced that the company will present at the following upcoming investor conferences.
- Rouven Bergmann, chief financial officer, will present at the Jefferies Technology Group 2017 Global Technology Conference on Tuesday, May 9, 2017, at 4:00 p.m. ET in Miami.
- Rouven Bergmann, chief financial officer, will present at the Needham Emerging Technology Conference on Tuesday, May 16, 2017, at 8:00 a.m. ET in New York.
- Tarek Sherif, chief executive officer, will present at the J.P. Morgan 45th Annual Global Technology, Media and Telecom Conference on Monday, May 22, 2017, at 3:00 p.m. ET in Boston.
A live audio webcast will be available on the “Investor” section of Medidata’s website at http://investor.mdsol.com. Please visit the website at least 15 minutes prior to the event to register, download and install any necessary audio or video software to access the presentation. For those unable to participate in the live webcast, a replay will be archived on the “Investor” section of Medidata’s website at http://investor.mdsol.com for a limited period of time following the conference.
Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 16 of the top 20 medical device developers—from study design and planning through execution, management and reporting.